Shanxi Zhendong Pharmaceutical Co.,Ltd (300158.SZ)
CNY 3.77
(3.86%)
CNY 3.77
(3.86%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 1.82 Billion CNY | -0.66% |
| 2022 | 1.83 Billion CNY | -39.5% |
| 2021 | 3.03 Billion CNY | 0.74% |
| 2020 | 3.01 Billion CNY | 5.87% |
| 2019 | 2.84 Billion CNY | 27.12% |
| 2018 | 2.24 Billion CNY | 3.6% |
| 2017 | 2.16 Billion CNY | 48.43% |
| 2016 | 1.45 Billion CNY | 41.15% |
| 2015 | 1.03 Billion CNY | 23.04% |
| 2014 | 839.45 Million CNY | 2.56% |
| 2013 | 818.52 Million CNY | 7.75% |
| 2012 | 759.65 Million CNY | 11.37% |
| 2011 | 682.1 Million CNY | 25.7% |
| 2010 | 542.62 Million CNY | 31.81% |
| 2009 | 411.66 Million CNY | 11.72% |
| 2008 | 368.48 Million CNY | 34.6% |
| 2007 | 273.75 Million CNY | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 347.21 Million CNY | -15.82% |
| 2024 Q2 | 399.02 Million CNY | 14.92% |
| 2024 Q3 | 408.15 Million CNY | 2.29% |
| 2023 Q3 | 464.14 Million CNY | -7.72% |
| 2023 Q2 | 502.96 Million CNY | 12.51% |
| 2023 Q4 | 412.46 Million CNY | -11.14% |
| 2023 Q1 | 447.02 Million CNY | 5.24% |
| 2023 FY | 1.82 Billion CNY | -0.66% |
| 2022 Q1 | 430.16 Million CNY | -13.83% |
| 2022 Q2 | 439.47 Million CNY | 2.16% |
| 2022 FY | 1.83 Billion CNY | -39.5% |
| 2022 Q4 | 424.75 Million CNY | -21.97% |
| 2022 Q3 | 544.31 Million CNY | 23.85% |
| 2021 Q1 | 798.15 Million CNY | -11.42% |
| 2021 Q3 | 871.7 Million CNY | 0.16% |
| 2021 FY | 3.03 Billion CNY | 0.74% |
| 2021 Q4 | 499.19 Million CNY | -42.73% |
| 2021 Q2 | 870.27 Million CNY | 9.04% |
| 2020 FY | 3.01 Billion CNY | 5.87% |
| 2020 Q2 | 658.76 Million CNY | 15.47% |
| 2020 Q1 | 570.47 Million CNY | -30.75% |
| 2020 Q3 | 886.7 Million CNY | 34.6% |
| 2020 Q4 | 901.06 Million CNY | 1.62% |
| 2019 Q1 | 560.1 Million CNY | -21.6% |
| 2019 FY | 2.84 Billion CNY | 27.12% |
| 2019 Q4 | 823.74 Million CNY | 9.16% |
| 2019 Q3 | 754.62 Million CNY | 6.08% |
| 2019 Q2 | 711.37 Million CNY | 27.01% |
| 2018 Q3 | 492.22 Million CNY | -8.44% |
| 2018 Q1 | 497.63 Million CNY | -45.19% |
| 2018 Q4 | 714.44 Million CNY | 45.14% |
| 2018 Q2 | 537.58 Million CNY | 8.03% |
| 2018 FY | 2.24 Billion CNY | 3.6% |
| 2017 Q4 | 907.97 Million CNY | 79.58% |
| 2017 Q2 | 451.89 Million CNY | 51.37% |
| 2017 FY | 2.16 Billion CNY | 48.43% |
| 2017 Q1 | 298.53 Million CNY | -52.58% |
| 2017 Q3 | 505.59 Million CNY | 11.89% |
| 2016 Q4 | 629.47 Million CNY | 71.47% |
| 2016 Q1 | 168.5 Million CNY | -57.92% |
| 2016 FY | 1.45 Billion CNY | 41.15% |
| 2016 Q2 | 292.8 Million CNY | 73.77% |
| 2016 Q3 | 367.1 Million CNY | 25.38% |
| 2015 Q2 | 262.31 Million CNY | 50.1% |
| 2015 FY | 1.03 Billion CNY | 23.04% |
| 2015 Q4 | 400.45 Million CNY | 105.01% |
| 2015 Q3 | 195.33 Million CNY | -25.53% |
| 2015 Q1 | 174.76 Million CNY | -33.54% |
| 2014 Q2 | 210.01 Million CNY | 40.03% |
| 2014 Q4 | 262.96 Million CNY | 21.46% |
| 2014 Q3 | 216.49 Million CNY | 3.08% |
| 2014 FY | 839.45 Million CNY | 2.56% |
| 2014 Q1 | 149.98 Million CNY | -46.27% |
| 2013 Q2 | 199.43 Million CNY | 32.59% |
| 2013 Q3 | 189.51 Million CNY | -4.97% |
| 2013 Q4 | 279.16 Million CNY | 47.31% |
| 2013 FY | 818.52 Million CNY | 7.75% |
| 2013 Q1 | 150.41 Million CNY | -43.6% |
| 2012 Q2 | 149.09 Million CNY | -2.2% |
| 2012 Q1 | 152.45 Million CNY | -3.43% |
| 2012 FY | 759.65 Million CNY | 11.37% |
| 2012 Q4 | 266.69 Million CNY | 39.34% |
| 2012 Q3 | 191.4 Million CNY | 28.37% |
| 2011 Q4 | 157.87 Million CNY | -33.41% |
| 2011 FY | 682.1 Million CNY | 25.7% |
| 2011 Q1 | 124.83 Million CNY | -16.0% |
| 2011 Q2 | 162.29 Million CNY | 30.01% |
| 2011 Q3 | 237.09 Million CNY | 46.09% |
| 2010 Q4 | 148.62 Million CNY | -3.4% |
| 2010 FY | 542.62 Million CNY | 31.81% |
| 2010 Q1 | 96.03 Million CNY | -17.97% |
| 2010 Q2 | 144.11 Million CNY | 50.06% |
| 2010 Q3 | 153.84 Million CNY | 6.75% |
| 2009 FY | 411.66 Million CNY | 11.72% |
| 2009 Q4 | 117.06 Million CNY | -3.12% |
| 2009 Q3 | 120.83 Million CNY | 0.0% |
| 2008 FY | 368.48 Million CNY | 34.6% |
| 2007 FY | 273.75 Million CNY | 0.0% |